These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 12083037)

  • 1. AIDS prevention more cost-effective than HAART treatment.
    AIDS Policy Law; 2002 Jun; 17(11):2. PubMed ID: 12083037
    [No Abstract]   [Full Text] [Related]  

  • 2. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.
    Beck EJ; Mandalia S; Gaudreault M; Brewer C; Zowall H; Gilmore N; Klein MB; Lalonde R; Piché A; Hankins CA
    AIDS; 2004 Dec; 18(18):2411-8. PubMed ID: 15622317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
    Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
    Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV prevention before HAART in sub-Saharan Africa.
    Marseille E; Hofmann PB; Kahn JG
    Lancet; 2002 May; 359(9320):1851-6. PubMed ID: 12044394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV prevention programs proven cost-effective.
    AIDS Alert; 1998 Sep; 13(9):107-8. PubMed ID: 11365792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience.
    Loubiere S; el Filal KM; Sodqi M; Loundou A; Luchini S; Cleary S; Moatti JP; Himmich H
    Antivir Ther; 2008; 13(2):241-51. PubMed ID: 18505175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
    Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Researchers explore cost-effective HIV preventions.
    AIDS Policy Law; 2005 Jul; 20(14):5. PubMed ID: 16108123
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in Thailand.
    Ono S; Kurotaki T; Nakasone T; Honda M; Boon-Long J; Sawanpanyalert P; Kimura K
    Jpn J Infect Dis; 2006 Jun; 59(3):168-73. PubMed ID: 16785697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda.
    Marseille E; Saba J; Muyingo S; Kahn JG
    AIDS; 2006 Apr; 20(6):907-14. PubMed ID: 16549976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia.
    Long EF; Brandeau ML; Galvin CM; Vinichenko T; Tole SP; Schwartz A; Sanders GD; Owens DK
    AIDS; 2006 Nov; 20(17):2207-15. PubMed ID: 17086061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is antiretroviral therapy cost-effective in South Africa?
    Braithwaite RS; Tsevat J
    PLoS Med; 2006 Jan; 3(1):e60. PubMed ID: 16435892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing costs and effectiveness of different starting points for highly active antiretroviral therapy in HIV-positive patients. Evidence from the ICONA cohort.
    Merito M; Pezzotti P;
    Eur J Health Econ; 2006 Mar; 7(1):30-6. PubMed ID: 16404620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of HIV post-exposure prophylaxis in France.
    Herida M; Larsen C; Lot F; Laporte A; Desenclos JC; Hamers FF
    AIDS; 2006 Aug; 20(13):1753-61. PubMed ID: 16931940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Balancing effectiveness and access to HIV treatment in the developing world.
    Hill A; Wood E
    AIDS; 2007 Jan; 21(3):361-3. PubMed ID: 17255743
    [No Abstract]   [Full Text] [Related]  

  • 16. AIDS is your business.
    Rosen S; Simon J; Vincent JR; MacLeod W; Fox M; Thea DM
    Harv Bus Rev; 2003 Feb; 81(2):80-7, 125. PubMed ID: 12577655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs and benefits of HAART for patients with HIV in a public hospital in Mexico.
    Aracena-Genao B; Navarro JO; Lamadrid-Figueroa H; Forsythe S; Trejo-Valdivia B
    AIDS; 2008 Jul; 22 Suppl 1():S141-8. PubMed ID: 18664946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent costs of HIV/AIDS-related health services in Rwanda: implications for financing.
    Quentin W; König HH; Schmidt JO; Kalk A
    Trop Med Int Health; 2008 Oct; 13(10):1245-56. PubMed ID: 18721185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The economics of effective AIDS treatment in Thailand.
    Over M; Revenga A; Masaki E; Peerapatanapokin W; Gold J; Tangcharoensathien V; Thanprasertsuk S
    AIDS; 2007 Jul; 21 Suppl 4():S105-16. PubMed ID: 17620745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 10 best resources in...cost analysis for HIV/AIDS programmes in low and middle income countries.
    Guinness L; Levine R; Weaver M
    Health Policy Plan; 2004 Jul; 19(4):242-5. PubMed ID: 15208280
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.